Abstract
A series of previously unreported di- and triaryl(hetaryl)cyclopentenone derivatives were prepared using a convenient synthetic method and screened preliminarily for antitumor activity in four human cell lines, i.e., T-cell leukemia (Jurkat), lung adenocarcinoma (A-549), colon cancer (HCT-116), and breast adenocarcinoma (MCF-7). The most cytotoxic of the tested compounds was 2-(3,4,5-trimethoxyphenyl)-3-(4-methoxyphenyl) cyclopent-2-en-1-one. However, it was inactive against lymphocytic leukemia P388 in mice despite its cytotoxicity in in vitro tests.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
